NLRP3 and metabolic dysfunction-associated steatotic liver disease: Likewise, pharmacological inhibition of NLRP3 inflammasome can also prevent HFD-induced non-alcoholic fatty liver disease with improved insulin sensitivity, and reduced liver damage accompanied by decreased caspase-1 activity and IL-1β expression levels versus wild-type mice [78].